Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
复制标题
DOI：
10.1002/ajh.25507
复制
发表时间：
2019-08-01
影响因子：
12.8
通讯作者：
Martinez-Lopez, Joaquin
中科院分区：
文献类型：
--
作者：
Alonso, Rafael;Teresa Cedena, Maria;Martinez-Lopez, Joaquin
多发性骨髓瘤（MM）中，通过骨髓造影和影像学分析确定的微小残留病（MRD）状态作为独立的预后因素的价值已得到很好的确立。然而，关于它们对更准确评估的潜在互补性的数据有限。为此，我们回顾性分析了PET-CT和MRD联合应用对103例新诊断MM患者预后的预测，并通过多参数流式细胞术（MFC）进行了评估。我们证实了无进展生存期（PFS）方面的获益，与MFC（风险比[HR] 0.53; 95%置信区间[CI]：0.28-0.98）和PET-CT（HR 0.18; 95% CI：0.09-0.36）的阴性结果相关。通过联合使用这两种技术，MRD-/ PET-患者的中位PFS为92个月，其中位PFS显著延长（P
The value of minimal residual disease (MRD) status by bonemarrowand imaging analysis as independent prognostic factors has been well established in multiple myeloma (MM). Nevertheless data about their potential complementarity for a more accurate assessment are limited. With this aim, we retrospectively analyzed the prediction of outcome with the combination of PET-CT and MRD, assessed by multiparameter flow cytometry (MFC) in 103 patients with newly diagnosedMM. We confirmed the benefit in terms of progression-free survival (PFS), linked to the achievement of negativity by MFC (hazard ratio [HR] 0.53; 95% confidence interval [CI]: 0.28-0.98), and PET-CT (HR 0.18; 95% CI: 0.09-0.36) individually. By combining both techniques, patients who became MRD-/ PET-, with a median of PFS 92 months, had significant prolongedmedian PFS (P